Abstract
No public abstract is available from the verified source records.
Raffaella Greco, Aiden Haghikia, Tobias Alexander, Nicoletta Del Papa, Andrea Doria, Christoph Heesen, Jörg Henes, Zora Marjanovic, Paolo A Muraro, Doron Rimar, Elisa Roldan, Fermin Sanchez-Guijo, Basil Sharrack, John A Snowden, Isabel Sánchez-Ortega, Marco Becilli, Agnès Bonnin, Krzysztof Kalwak, Bruce L Levine, Johanna Richter, Tuula Rintala, Annalisa Ruggeri, Georg Schett, Dominique Farge
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Autoimmune diseases: the failure of self tolerance
10.1126/science.1972595 · 1990
Defining criteria for autoimmune diseases (Witebsky's postulates revisited)
10.1016/0167-5699(93)90244-f · 1993
Cell therapy for autoimmune diseases: does it have a future?
10.1136/ard.2004.028340 · 2004
Treatment of severe autoimmune disease by stem-cell transplantation
10.1038/nature03728 · 2005
Immunoablation followed or not by hematopoietic stem cells as an intense therapy for severe autoimmune diseases. New perspectives, new problems
2001
Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations
10.1038/s41409-025-02701-3 · 2025
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT
10.1038/s41582-024-01050-x · 2025
Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee
10.1038/s41409-025-02695-y · 2025
CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus
10.1056/nejmc2107725 · 2021
CAR T-cell therapy in autoimmune diseases
10.1016/s0140-6736(23)01126-1 · 2023
CD19 CAR T-Cell therapy in autoimmune disease - a case series with follow-up
10.1056/nejmoa2308917 · 2024
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial
10.1038/s41591-025-04185-6 · 2026
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
10.1038/s41591-022-02017-5 · 2022
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
10.1136/ard-2024-226142 · 2025
Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee
10.1016/j.eclinm.2024.102476 · 2024
Autologous CD19-Targeting CAR T cells in a patient with refractory juvenile dermatomyositis
10.1002/art.42933 · 2024
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma
10.1182/blood.2025028375 · 2025
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapy
10.1038/s41409-023-01958-w · 2023
10.1016/j.annonc.2021.12.003
10.1016/j.annonc.2021.12.003 · 2022
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
10.1182/blood.2023020578 · 2023
Large volume leukapheresis is efficient and safe even in small children up to 15 kg body weight
2017
Leukapheresis in children weighing less than 20 kg
10.1002/pbc.24048 · 2012
Consensus-based recommendations for the management of juvenile systemic sclerosis
10.1093/rheumatology/keaa584 · 2021
Definition and initial validation of a lupus low disease activity state (LLDAS)
10.1136/annrheumdis-2015-207726 · 2016
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
10.1016/s1474-4422(24)00140-6 · 2024
The role of chimeric antigen receptor T-cell therapy in immune-mediated neurological diseases
10.1002/ana.27029 · 2024
Myasthenia gravis: recommendations for clinical research standards
10.1212/wnl.55.1.16 · 2000
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria
10.1016/s1474-4422(25)00270-4 · 2025
How I treat refractory immune thrombocytopenia
10.1182/blood-2016-03-603365 · 2016
Refractory ITP: revisiting definitions, diagnostics, and management paradigms
10.1182/hematology.2025000720 · 2025
Thrombopoietin and hematopoietic stem cells
10.4161/cc.10.10.15619 · 2011
Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study
10.1182/bloodadvances.2024014984 · 2025
Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA's conclusions from the evaluation of 38 suspected cases
10.1038/s41434-025-00586-x · 2026
How I treat cold agglutinin disease
10.1182/blood.2019003809 · 2021
Management of autoimmune hemolytic anemia
10.1182/hematology.2025000719 · 2025
International recommendations on the diagnosis and treatment of acquired hemophilia A
10.3324/haematol.2019.230771 · 2020
CD19 CAR T-Cell therapy in multidrug-resistant ulcerative colitis
10.1056/nejmc2508023 · 2025
CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement
10.1016/j.jhep.2025.11.027 · 2025
Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing
10.1016/j.jcyt.2022.05.003 · 2022
10.1016/j.bulcan.2023.09.002
10.1016/j.bulcan.2023.09.002 · 2024
In Vivo CD19 CAR T-cell therapy for refractory systemic lupus erythematosus
10.1056/nejmc2509522 · doi-reference
Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells
10.1038/s41587-022-01637-z · doi-reference
CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy
10.1016/j.jaut.2025.103369 · doi-reference
CD4+ CD7- CD28- T cells are expanded in rheumatoid arthritis and are characterized by autoreactivity
10.1172/jci118638 · doi-reference
CAR-γδ T cells: a new paradigm of programmable innate immune sentinels and their systemic applications in cancer and beyond
10.3389/fimmu.2025.1735763 · doi-reference
Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus
10.1038/s41467-024-46448-9 · doi-reference
Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China
10.1016/s0140-6736(25)01671-x · doi-reference
Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products
10.3389/fimmu.2025.1512494 · doi-reference
Relapse after anti-CD19 CAR T-cell therapy in a patient with severe rheumatoid arthritis and multiple sclerosis effectively treated by autologous stem cell transplantation
10.1016/j.ard.2025.03.018 · doi-reference
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia
10.1182/bloodadvances.2024012885 · doi-reference
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation
10.1136/jitc-2021-004483 · doi-reference
Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies
10.1172/jci.insight.146743 · doi-reference
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma
10.1182/bloodadvances.2021004603 · doi-reference
Successful generation of CD19 chimeric antigen receptor T cells from patients with advanced systemic lupus erythematosus
10.1016/j.jtct.2022.10.004 · doi-reference
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
10.3389/fimmu.2025.1688995 · doi-reference
New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies
10.1186/s40164-024-00573-9 · doi-reference
Allogeneic CAR T cells: a new player in the field and the peculiar opportunities of the hospital exemption path
10.1016/j.ymthe.2025.05.018 · doi-reference
Illness perception and psychological distress in adolescents with systemic lupus erythematosus
10.1177/09612033251325313 · doi-reference
Implications of inflammatory processes on a developing central nervous system in childhood-onset systemic lupus erythematosus
10.1002/art.42736 · doi-reference
Body composition in long-standing juvenile dermatomyositis: associations with disease activity, muscle strength and cardiometabolic measures
10.1093/rheumatology/keab805 · doi-reference
New comorbidity index associated with survival after chimeric antigen receptor t-cell therapy for large b-cell lymphoma
10.1182/bloodadvances.2024015599 · doi-reference
Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results
10.1038/s41392-022-01278-3 · doi-reference
BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells
10.1038/s41591-025-03718-3 · doi-reference
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma
10.1038/s41591-022-01959-0 · doi-reference
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity
10.1182/bloodadvances.2024012637 · doi-reference
Association of CD19+-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality
10.1016/j.jaci.2024.10.021 · doi-reference
Durable response to CAR T is associated with elevated activation and clonotypic expansion of the cytotoxic native T cell repertoire
10.1038/s41467-025-59904-x · doi-reference
The landscape of immune monitoring in CAR-T cell therapy: a comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT
10.1016/j.blre.2025.101272 · doi-reference
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
10.1038/s41408-024-01193-6 · doi-reference
CAR T cell therapy-related cardiovascular outcomes and management: systemic disease or direct cardiotoxicity?
10.1016/j.jaccao.2020.02.011 · doi-reference
Immunological consequences of CAR T-cell therapy: an analysis of infectious complications and immune reconstitution
10.1182/bloodadvances.2024015346 · doi-reference
Overview of infectious complications among CAR T- cell therapy recipients
10.3389/fonc.2024.1398078 · doi-reference
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies
10.1053/j.seminhematol.2023.02.003 · doi-reference
Infections in haematology patients treated with CAR-T therapies: a systematic review and meta-analysis
10.1016/j.critrevonc.2023.104134 · doi-reference
The U.S. Food and Drug Administration's perspective on chimeric antigen receptor T-cell therapies for autoimmune and rheumatic conditions
10.7326/annals-25-04559 · doi-reference
Risk of second tumors and T-cell Lymphoma after CAR T-cell therapy
10.1056/nejmoa2401361 · doi-reference
Aggressive Lymphoma after CD19 CAR T-Cell Therapy
10.1056/nejmoa2402730 · doi-reference
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
10.1038/s41591-023-02767-w · doi-reference
Indolent CD4+ CAR T-Cell lymphoma after cilta-cel CAR T-cell therapy
10.1056/nejmoa2401530 · doi-reference
Managing IEC-associated enterocolitis following CAR-T therapy in multiple myeloma
10.1038/s41408-025-01320-x · doi-reference